newsfilter
← Latest News
GlobeNewswire·

Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Achieved substantial enrollment in FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC; topline results from interim analysis expected in mid-2027 Enrolling FORTIFI-FLEX alternate dosing study; expect to have data